ID   MYCB2_HUMAN             Reviewed;        4678 AA.
AC   O75592; A6NJC6; Q5JSX8; Q5VZN6; Q6PIB6; Q9UQ11; Q9Y6E4;
DT   21-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   20-JUN-2018, sequence version 4.
DT   28-JUN-2023, entry version 207.
DE   RecName: Full=E3 ubiquitin-protein ligase MYCBP2 {ECO:0000305};
DE            EC=2.3.2.33 {ECO:0000269|PubMed:29643511};
DE   AltName: Full=Myc-binding protein 2 {ECO:0000305};
DE   AltName: Full=Protein associated with Myc {ECO:0000303|PubMed:9689053};
GN   Name=MYCBP2 {ECO:0000312|HGNC:HGNC:23386};
GN   Synonyms=KIAA0916 {ECO:0000303|PubMed:12168954}, PAM
GN   {ECO:0000303|PubMed:9689053};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH MYC,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9689053; DOI=10.1073/pnas.95.16.9172;
RA   Guo Q., Xie J., Dang C.V., Liu E.T., Bishop J.M.;
RT   "Identification of a large Myc-binding protein that contains RCC1-like
RT   repeats.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9172-9177(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM 2).
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3469-4678 (ISOFORM 1).
RC   TISSUE=Brain {ECO:0000269|PubMed:10048485};
RX   PubMed=10048485; DOI=10.1093/dnares/5.6.355;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 5:355-364(1998).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3827-4678 (ISOFORM 1).
RC   TISSUE=Brain {ECO:0000312|EMBL:AAH37971.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4405-4678.
RC   TISSUE=Umbilical cord blood {ECO:0000269|PubMed:11042152};
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for 300
RT   previously undefined genes expressed in CD34+ hematopoietic stem/progenitor
RT   cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [8]
RP   INTERACTION WITH TSC2.
RX   PubMed=14559897; DOI=10.1074/jbc.m310208200;
RA   Murthy V., Han S., Beauchamp R.L., Smith N., Haddad L.A., Ito N.,
RA   Ramesh V.;
RT   "Pam and its ortholog highwire interact with and may negatively regulate
RT   the TSC1.TSC2 complex.";
RL   J. Biol. Chem. 279:1351-1358(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3090, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   FUNCTION, AND AUTOUBIQUITINATION.
RX   PubMed=18308511; DOI=10.1016/j.cellsig.2008.01.020;
RA   Han S., Witt R.M., Santos T.M., Polizzano C., Sabatini B.L., Ramesh V.;
RT   "Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and
RT   regulates TSC/mTOR signaling.";
RL   Cell. Signal. 20:1084-1091(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3505, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-181; SER-183;
RP   THR-2683; SER-2789; SER-3478 AND SER-3505, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH FBXO45.
RX   PubMed=19398581; DOI=10.1128/mcb.00364-09;
RA   Saiga T., Fukuda T., Matsumoto M., Tada H., Okano H.J., Okano H.,
RA   Nakayama K.I.;
RT   "Fbxo45 forms a novel ubiquitin ligase complex and is required for neuronal
RT   development.";
RL   Mol. Cell. Biol. 29:3529-3543(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3505, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-2683; SER-2920 AND SER-3505,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   FUNCTION.
RX   PubMed=20534529; DOI=10.1073/pnas.1000438107;
RA   Yin L., Joshi S., Wu N., Tong X., Lazar M.A.;
RT   "E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the
RT   circadian heme receptor Rev-erb alpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11614-11619(2010).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-2683 AND SER-3505, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   INTERACTION WITH RAE1.
RX   PubMed=22357847; DOI=10.1523/jneurosci.2901-11.2012;
RA   Grill B., Chen L., Tulgren E.D., Baker S.T., Bienvenut W., Anderson M.,
RA   Quadroni M., Jin Y., Garner C.C.;
RT   "RAE-1, a novel PHR binding protein, is required for axon termination and
RT   synapse formation in Caenorhabditis elegans.";
RL   J. Neurosci. 32:2628-2636(2012).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127; SER-1624; THR-2683;
RP   SER-2769; SER-2787; SER-2789; SER-2833; SER-2839; SER-2871; SER-2985;
RP   SER-3505; SER-3931 AND SER-3932, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3478, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   FUNCTION, INTERACTION WITH RAN AND RANGAP1, AND SUBCELLULAR LOCATION.
RX   PubMed=26304119; DOI=10.1074/jbc.m115.646901;
RA   Doerr A., Pierre S., Zhang D.D., Henke M., Holland S., Scholich K.;
RT   "MYCBP2 is a guanosine exchange factor for Ran protein and determines its
RT   localization in neurons of dorsal root ganglia.";
RL   J. Biol. Chem. 290:25620-25635(2015).
RN   [25]
RP   INTERACTION WITH ATP13A2.
RX   PubMed=27278822; DOI=10.1038/ncomms11803;
RA   Bento C.F., Ashkenazi A., Jimenez-Sanchez M., Rubinsztein D.C.;
RT   "The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate
RT   autophagy via a common pathway.";
RL   Nat. Commun. 7:11803-11803(2016).
RN   [26]
RP   INTERACTION WITH USP11.
RX   PubMed=29293652; DOI=10.1371/journal.pone.0190513;
RA   Stockum A., Snijders A.P., Maertens G.N.;
RT   "USP11 deubiquitinates RAE1 and plays a key role in bipolar spindle
RT   formation.";
RL   PLoS ONE 13:e0190513-e0190513(2018).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 4416-4678 IN COMPLEX WITH ZINC,
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITES, ZINC-BINDING, AND MUTAGENESIS
RP   OF CYS-4558; GLU-4572; CYS-4610; PHE-4611; PHE-4616; HIS-4621 AND PHE-4624.
RX   PubMed=29643511; DOI=10.1038/s41586-018-0026-1;
RA   Pao K.C., Wood N.T., Knebel A., Rafie K., Stanley M., Mabbitt P.D.,
RA   Sundaramoorthy R., Hofmann K., van Aalten D.M.F., Virdee S.;
RT   "Activity-based E3 ligase profiling uncovers an E3 ligase with
RT   esterification activity.";
RL   Nature 556:381-385(2018).
CC   -!- FUNCTION: Atypical E3 ubiquitin-protein ligase which specifically
CC       mediates ubiquitination of threonine and serine residues on target
CC       proteins, instead of ubiquitinating lysine residues (PubMed:29643511).
CC       Shows esterification activity towards both threonine and serine, with a
CC       preference for threonine, and acts via two essential catalytic cysteine
CC       residues that relay ubiquitin to its substrate via thioester
CC       intermediates (PubMed:29643511). Interacts with the E2 enzymes UBE2D1,
CC       UBE2D3, UBE2E1 and UBE2L3 (PubMed:18308511, PubMed:29643511). Plays a
CC       key role in neural development, probably by mediating ubiquitination of
CC       threonine residues on target proteins (Probable). Involved in different
CC       processes such as regulation of neurite outgrowth, synaptic growth,
CC       synaptogenesis and axon degeneration (By similarity). Required for the
CC       formation of major central nervous system axon tracts (By similarity).
CC       Required for proper axon growth by regulating axon navigation and axon
CC       branching: acts by regulating the subcellular location and stability of
CC       MAP3K12/DLK (By similarity). Required for proper localization of
CC       retinogeniculate projections but not for eye-specific segregation (By
CC       similarity). Regulates axon guidance in the olfactory system (By
CC       similarity). Involved in Wallerian axon degeneration, an evolutionarily
CC       conserved process that drives the loss of damaged axons: acts by
CC       promoting destabilization of NMNAT2, probably via ubiquitination of
CC       NMNAT2 (By similarity). Catalyzes ubiquitination of threonine and/or
CC       serine residues on NMNAT2, consequences of threonine and/or serine
CC       ubiquitination are however unknown (PubMed:29643511). Regulates the
CC       internalization of TRPV1 in peripheral sensory neurons (By similarity).
CC       Mediates ubiquitination and subsequent proteasomal degradation of
CC       TSC2/tuberin (PubMed:18308511, PubMed:27278822). Independently of the
CC       E3 ubiquitin-protein ligase activity, also acts as a guanosine exchange
CC       factor (GEF) for RAN in neurons of dorsal root ganglia
CC       (PubMed:26304119). May function as a facilitator or regulator of
CC       transcriptional activation by MYC (PubMed:9689053). Acts in concert
CC       with HUWE1 to regulate the circadian clock gene expression by promoting
CC       the lithium-induced ubiquination and degradation of NR1D1
CC       (PubMed:20534529). {ECO:0000250|UniProtKB:Q7TPH6,
CC       ECO:0000269|PubMed:18308511, ECO:0000269|PubMed:20534529,
CC       ECO:0000269|PubMed:26304119, ECO:0000269|PubMed:27278822,
CC       ECO:0000269|PubMed:29643511, ECO:0000269|PubMed:9689053}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[E2 ubiquitin-conjugating enzyme]-S-ubiquitinyl-L-cysteine +
CC         [acceptor protein]-L-threonine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + [acceptor protein]-3-O-ubiquitinyl-L-threonine.;
CC         EC=2.3.2.33; Evidence={ECO:0000269|PubMed:29643511};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:18308511, ECO:0000269|PubMed:29643511}.
CC   -!- SUBUNIT: Interacts with MYC (PubMed:9689053). Interacts with TSC2
CC       (tuberin) when TSC2 is in complex with TSC1 (hamartin)
CC       (PubMed:14559897). Interacts with FBXO45 (PubMed:19398581). Interacts
CC       with RAE1 (PubMed:22357847). Interacts with CPNE1 (via VWFA domain) and
CC       CPNE4 (via VWFA domain) (By similarity). Interacts with (sumoylated)
CC       RANGAP1; interaction with sumoylated RANGAP1 inhibits E3 ubiquitin-
CC       protein ligase activity and promotes MYCBP2 translocation to the
CC       nucleus (PubMed:26304119). Interacts with RAN
CC       (PubMed:26304119).Interacts with ATP13A2; the interaction inhibits the
CC       ubiquitination of TSC2 by MYCBP2 (PubMed:27278822). Interacts with
CC       USP11 (PubMed:29293652). {ECO:0000250|UniProtKB:Q7TPH6,
CC       ECO:0000269|PubMed:14559897, ECO:0000269|PubMed:19398581,
CC       ECO:0000269|PubMed:22357847, ECO:0000269|PubMed:26304119,
CC       ECO:0000269|PubMed:27278822, ECO:0000269|PubMed:29293652,
CC       ECO:0000269|PubMed:9689053}.
CC   -!- INTERACTION:
CC       O75592; P63104: YWHAZ; NbExp=2; IntAct=EBI-1043774, EBI-347088;
CC       O75592; Q3SWS8: Rae1; Xeno; NbExp=2; IntAct=EBI-1043774, EBI-6920222;
CC       O75592; PRO_0000045603 [Q99IB8]; Xeno; NbExp=3; IntAct=EBI-1043774, EBI-6927928;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:26304119,
CC       ECO:0000269|PubMed:9689053}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q7TPH6}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:Q7TPH6}. Note=Localizes to axon shafts and
CC       associates with microtubule cytoskeleton (By similarity). Translocates
CC       to the nucleus following interaction with sumoylated RANGAP1
CC       (PubMed:26304119). {ECO:0000250|UniProtKB:Q7TPH6,
CC       ECO:0000269|PubMed:26304119}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1 {ECO:0000269|PubMed:9689053};
CC         IsoId=O75592-1; Sequence=Displayed;
CC       Name=2 {ECO:0000305};
CC         IsoId=O75592-2; Sequence=VSP_014183;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined, expression is
CC       exceptionally abundant in brain and thymus. Colocalizes with TSC1 and
CC       TSC2 along the neurites and in the growth cones. Highly expressed in
CC       peripheral and central neurons. Colocalized with TSC1 in one of the
CC       filopodial extensions at the tip of a growth cone.
CC       {ECO:0000269|PubMed:9689053}.
CC   -!- DOMAIN: The PHR domains are compact beta-sandwich folds composed of 11
CC       antiparallel strands and decorated with conserved apical loops. They
CC       are likely to play a structural role and mediate interactions with
CC       substrates or partners (By similarity). {ECO:0000250|UniProtKB:Q7TPH6}.
CC   -!- DOMAIN: The tandem cysteine domain region confers threonine specificity
CC       and contains the two essential catalytic cysteine residues that relay
CC       ubiquitin. It binds four zinc ions in a C5HC7HC2 configuration.
CC       {ECO:0000269|PubMed:29643511}.
CC   -!- PTM: Autoubiquitinated. {ECO:0000269|PubMed:18308511}.
CC   -!- SIMILARITY: Belongs to the RING-Cys relay (RCR) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD39842.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAH37971.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAI39758.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF075587; AAC39928.1; -; mRNA.
DR   EMBL; AL159154; CAH73736.1; -; Genomic_DNA.
DR   EMBL; AL159158; CAH73736.1; JOINED; Genomic_DNA.
DR   EMBL; AL359257; CAH73736.1; JOINED; Genomic_DNA.
DR   EMBL; AC001226; CAH73736.1; JOINED; Genomic_DNA.
DR   EMBL; AL159158; CAI16842.1; -; Genomic_DNA.
DR   EMBL; AL159154; CAI16842.1; JOINED; Genomic_DNA.
DR   EMBL; AL359257; CAI16842.1; JOINED; Genomic_DNA.
DR   EMBL; AC001226; CAI16842.1; JOINED; Genomic_DNA.
DR   EMBL; AL359257; CAI39759.1; -; Genomic_DNA.
DR   EMBL; AL159158; CAI39759.1; JOINED; Genomic_DNA.
DR   EMBL; AL159154; CAI39759.1; JOINED; Genomic_DNA.
DR   EMBL; AC001226; CAI39759.1; JOINED; Genomic_DNA.
DR   EMBL; AL359257; CAI39758.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC001226; CAI39758.1; JOINED; Genomic_DNA.
DR   EMBL; CH471093; EAW80565.1; -; Genomic_DNA.
DR   EMBL; AB020723; BAA74939.1; -; mRNA.
DR   EMBL; BC037971; AAH37971.1; ALT_INIT; mRNA.
DR   EMBL; AF083244; AAD39842.1; ALT_FRAME; mRNA.
DR   RefSeq; NP_055872.4; NM_015057.4. [O75592-1]
DR   PDB; 5O6C; X-ray; 1.75 A; A=4416-4678.
DR   PDB; 6T7F; X-ray; 2.58 A; A=4423-4678.
DR   PDBsum; 5O6C; -.
DR   PDBsum; 6T7F; -.
DR   SMR; O75592; -.
DR   BioGRID; 116709; 222.
DR   DIP; DIP-28142N; -.
DR   IntAct; O75592; 117.
DR   MINT; O75592; -.
DR   STRING; 9606.ENSP00000444596; -.
DR   GlyCosmos; O75592; 1 site, 1 glycan.
DR   GlyGen; O75592; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; O75592; -.
DR   MetOSite; O75592; -.
DR   PhosphoSitePlus; O75592; -.
DR   SwissPalm; O75592; -.
DR   BioMuta; MYCBP2; -.
DR   EPD; O75592; -.
DR   jPOST; O75592; -.
DR   MassIVE; O75592; -.
DR   MaxQB; O75592; -.
DR   PaxDb; O75592; -.
DR   PeptideAtlas; O75592; -.
DR   ProteomicsDB; 50101; -. [O75592-1]
DR   ProteomicsDB; 50102; -. [O75592-2]
DR   Antibodypedia; 24520; 67 antibodies from 12 providers.
DR   DNASU; 23077; -.
DR   Ensembl; ENST00000544440.7; ENSP00000444596.2; ENSG00000005810.20. [O75592-1]
DR   GeneID; 23077; -.
DR   KEGG; hsa:23077; -.
DR   MANE-Select; ENST00000544440.7; ENSP00000444596.2; NM_015057.5; NP_055872.4.
DR   UCSC; uc058xok.1; human. [O75592-1]
DR   AGR; HGNC:23386; -.
DR   CTD; 23077; -.
DR   DisGeNET; 23077; -.
DR   GeneCards; MYCBP2; -.
DR   HGNC; HGNC:23386; MYCBP2.
DR   HPA; ENSG00000005810; Low tissue specificity.
DR   MIM; 610392; gene.
DR   neXtProt; NX_O75592; -.
DR   OpenTargets; ENSG00000005810; -.
DR   PharmGKB; PA134871126; -.
DR   VEuPathDB; HostDB:ENSG00000005810; -.
DR   eggNOG; KOG1428; Eukaryota.
DR   GeneTree; ENSGT00940000155756; -.
DR   HOGENOM; CLU_000063_0_0_1; -.
DR   InParanoid; O75592; -.
DR   OMA; MAHPGCG; -.
DR   OrthoDB; 167377at2759; -.
DR   PhylomeDB; O75592; -.
DR   TreeFam; TF313151; -.
DR   BRENDA; 2.3.2.33; 2681.
DR   PathwayCommons; O75592; -.
DR   SignaLink; O75592; -.
DR   SIGNOR; O75592; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 23077; 13 hits in 340 CRISPR screens.
DR   ChiTaRS; MYCBP2; human.
DR   GeneWiki; MYCBP2; -.
DR   GenomeRNAi; 23077; -.
DR   Pharos; O75592; Tbio.
DR   PRO; PR:O75592; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; O75592; protein.
DR   Bgee; ENSG00000005810; Expressed in Brodmann (1909) area 23 and 207 other tissues.
DR   ExpressionAtlas; O75592; baseline and differential.
DR   Genevisible; O75592; HS.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IC:UniProt.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0021785; P:branchiomotor neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0021952; P:central nervous system projection neuron axonogenesis; ISS:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0050905; P:neuromuscular process; ISS:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProt.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:1902667; P:regulation of axon guidance; ISS:UniProtKB.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0032880; P:regulation of protein localization; IEA:Ensembl.
DR   GO; GO:0008582; P:regulation of synaptic assembly at neuromuscular junction; IBA:GO_Central.
DR   CDD; cd19799; Bbox2_MYCBP2; 1.
DR   CDD; cd16463; RING-H2_PHR; 1.
DR   Gene3D; 2.60.120.260; Galactose-binding domain-like; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR   Gene3D; 2.60.120.820; PHR domain; 2.
DR   Gene3D; 2.130.10.30; Regulator of chromosome condensation 1/beta-lactamase-inhibitor protein II; 2.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR004939; APC_su10/DOC_dom.
DR   InterPro; IPR017868; Filamin/ABP280_repeat-like.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR012983; PHR.
DR   InterPro; IPR038648; PHR_sf.
DR   InterPro; IPR009091; RCC1/BLIP-II.
DR   InterPro; IPR000408; Reg_chr_condens.
DR   InterPro; IPR003646; SH3-like_bac-type.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR45943; E3 UBIQUITIN-PROTEIN LIGASE MYCBP2; 1.
DR   PANTHER; PTHR45943:SF1; E3 UBIQUITIN-PROTEIN LIGASE MYCBP2; 1.
DR   Pfam; PF03256; ANAPC10; 1.
DR   Pfam; PF08005; PHR; 2.
DR   Pfam; PF00415; RCC1; 1.
DR   Pfam; PF13540; RCC1_2; 1.
DR   Pfam; PF08239; SH3_3; 1.
DR   Pfam; PF13639; zf-RING_2; 1.
DR   PRINTS; PR00633; RCCNDNSATION.
DR   SMART; SM01337; APC10; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF81296; E set domains; 1.
DR   SUPFAM; SSF49785; Galactose-binding domain-like; 1.
DR   SUPFAM; SSF50985; RCC1/BLIP-II; 1.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   PROSITE; PS51284; DOC; 1.
DR   PROSITE; PS50194; FILAMIN_REPEAT; 1.
DR   PROSITE; PS00626; RCC1_2; 2.
DR   PROSITE; PS50012; RCC1_3; 3.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Biological rhythms; Cell projection;
KW   Cytoplasm; Cytoskeleton; Disulfide bond;
KW   Guanine-nucleotide releasing factor; Metal-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..4678
FT                   /note="E3 ubiquitin-protein ligase MYCBP2"
FT                   /id="PRO_0000055963"
FT   REPEAT          600..655
FT                   /note="RCC1 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          699..755
FT                   /note="RCC1 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          907..957
FT                   /note="RCC1 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          958..1008
FT                   /note="RCC1 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1010..1066
FT                   /note="RCC1 5"
FT                   /evidence="ECO:0000255"
FT   REPEAT          2341..2443
FT                   /note="Filamin"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          3719..3897
FT                   /note="DOC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00614"
FT   ZN_FING         4428..4479
FT                   /note="RING-type; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          87..127
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          172..192
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          609..628
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          898..928
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1235..1386
FT                   /note="PHR domain 1"
FT                   /evidence="ECO:0000250"
FT   REGION          1726..1884
FT                   /note="PHR domain 2"
FT                   /evidence="ECO:0000250"
FT   REGION          1993..2012
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2022..2550
FT                   /note="RAE1 binding"
FT                   /evidence="ECO:0000269|PubMed:22357847"
FT   REGION          2321..2340
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2709..2931
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2943..2963
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2979..3020
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3066..3086
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3605..3631
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3915..3934
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4539..4676
FT                   /note="Tandem cysteine domain"
FT                   /evidence="ECO:0000305|PubMed:29643511"
FT   COMPBIAS        102..121
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        614..628
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        908..924
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2714..2735
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2736..2757
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2783..2815
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2823..2856
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2860..2890
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2901..2923
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        3919..3933
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        4558
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   ACT_SITE        4610
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   BINDING         4428
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4431
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4446
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4448
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4451
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4454
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4475
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4478
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4544
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4547
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4575
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4578
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4587
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4590
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4599
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4602
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4603
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4617
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4620
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4638
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4652
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4658
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="6"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4669
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   BINDING         4672
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000269|PubMed:29643511,
FT                   ECO:0007744|PDB:5O6C"
FT   SITE            4611
FT                   /note="Important for catalysis"
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   SITE            4616
FT                   /note="Important for catalysis"
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   SITE            4624
FT                   /note="Important for catalysis"
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   MOD_RES         127
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         181
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         183
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1624
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2683
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2769
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2787
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2789
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2833
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2839
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2869
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7TPH6"
FT   MOD_RES         2871
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2920
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         2985
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         3090
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         3478
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         3505
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         3921
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7TPH6"
FT   MOD_RES         3931
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         3932
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   DISULFID        1748..1863
FT                   /evidence="ECO:0000250|UniProtKB:Q7TPH6"
FT   VAR_SEQ         3939..3941
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_014183"
FT   VARIANT         1919
FT                   /note="A -> S (in dbSNP:rs35887505)"
FT                   /id="VAR_052086"
FT   VARIANT         2626
FT                   /note="V -> M (in dbSNP:rs9574002)"
FT                   /id="VAR_030070"
FT   MUTAGEN         4558
FT                   /note="C->S: Abolished E3 ubiquitin-protein ligase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   MUTAGEN         4572
FT                   /note="E->A,Q: Does not affect E3 ubiquitin-protein ligase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   MUTAGEN         4610
FT                   /note="C->A: Increased thiol-sensitive adduct formation."
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   MUTAGEN         4610
FT                   /note="C->S: Retains activity while also forming a discrete
FT                   monoubiquitin adduct that is resistant to thiolysis but is
FT                   reversible after base treatment."
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   MUTAGEN         4611
FT                   /note="F->A: Reduced E3 ubiquitin-protein ligase activity
FT                   in threonine discharge assay."
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   MUTAGEN         4616
FT                   /note="F->A: Reduced E3 ubiquitin-protein ligase activity
FT                   in threonine discharge assay."
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   MUTAGEN         4621
FT                   /note="H->N: Abolished E3 ubiquitin-protein ligase activity
FT                   in threonine discharge assay, associated with enhanced
FT                   thiol-sensitive ubiquitin adduct formation."
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   MUTAGEN         4624
FT                   /note="F->A: Reduced E3 ubiquitin-protein ligase activity
FT                   in threonine discharge assay."
FT                   /evidence="ECO:0000269|PubMed:29643511"
FT   CONFLICT        61
FT                   /note="R -> P (in Ref. 1; AAC39928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        240
FT                   /note="G -> V (in Ref. 1; AAC39928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        510
FT                   /note="G -> R (in Ref. 1; AAC39928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        618
FT                   /note="T -> I (in Ref. 1; AAC39928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        903..904
FT                   /note="QL -> HV (in Ref. 1; AAC39928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1512..1513
FT                   /note="GV -> PL (in Ref. 1; AAC39928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2139
FT                   /note="K -> M (in Ref. 1; AAC39928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3201
FT                   /note="E -> GR (in Ref. 1; AAC39928)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3645
FT                   /note="A -> R (in Ref. 1; AAC39928)"
FT                   /evidence="ECO:0000305"
FT   TURN            4429..4431
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4432..4435
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4436..4438
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4441..4443
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4449..4451
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4452..4461
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4464..4467
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4471..4473
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   TURN            4476..4478
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4485..4487
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4488..4511
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4518..4521
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   TURN            4526..4529
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4531..4538
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4539..4543
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   TURN            4545..4547
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4550..4555
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   TURN            4559..4562
FT                   /evidence="ECO:0007829|PDB:6T7F"
FT   HELIX           4570..4572
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4577..4579
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   TURN            4588..4590
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   TURN            4592..4594
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4595..4598
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4602..4605
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4608..4610
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   TURN            4611..4613
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4614..4616
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4618..4622
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4624..4629
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4632..4634
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4638..4641
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4642..4644
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4648..4650
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   STRAND          4666..4669
FT                   /evidence="ECO:0007829|PDB:5O6C"
FT   HELIX           4672..4674
FT                   /evidence="ECO:0007829|PDB:5O6C"
SQ   SEQUENCE   4678 AA;  513636 MW;  F76B95A12613E74B CRC64;
     MMMCAATASP AAASSGLGGD GFYPAATFSS SPAPGALFMP VPDGSVAAAG LGLGLPAADS
     RGHYQLLLSG RALADRYRRI YTAALNDRDQ GGGSAGHPAS RNKKILNKKK LKRKQKSKSK
     VKTRSKSENL ENTVIIPDIK LHSNPSAFNI YCNVRHCVLE WQKKEISLAA ASKNSVQSGE
     SDSDEEEESK EPPIKLPKII EVGLCEVFEL IKETRFSHPS LCLRSLQALL NVLQGQQPEG
     LQSEPPEVLE SLFQLLLEIT VRSTGMNDST GQSLTALSCA CLFSLVASWG ETGRTLQAIS
     AILTNNGSHA CQTIQVPTIL NSLQRSVQAV LVGKIQIQDW FSNGIKKAAL MHKWPLKEIS
     VDEDDQCLLQ NDGFFLYLLC KDGLYKIGSG YSGTVRGHIY NSTSRIRNRK EKKSWLGYAQ
     GYLLYRDVNN HSMTAIRISP ETLEQDGTVM LPDCHTEGQN ILFTDGEYIN QIAASRDDGF
     VVRIFATSTE PVLQQELQLK LARKCLHACG ISLFDLEKDL HIISTGFDEE SAILGAGREF
     ALMKTANGKI YYTGKYQSLG IKQGGPSAGK WVELPITKSP KIVHFSVGHD GSHALLVAED
     GSIFFTGSAS KGEDGESTKS RRQSKPYKPK KIIKMEGKIV VYTACNNGSS SVISKDGELY
     MFGKDAIYSD SSSLVTDLKG HFVTQVAMGK AHTCVLMKNG EVWTFGVNNK GQCGRDTGAM
     NQGGKGFGVE NMATAMDEDL EEELDEKDEK SMMCPPGMHK WKLEQCMVCT VCGDCTGYGA
     SCVSSGRPDR VPGGICGCGS GESGCAVCGC CKACARELDG QEARQRGILD AVKEMIPLDL
     LLAVPVPGVN IEEHLQLRQE EKRQRVIRRH RLEEGRGPLV FAGPIFMNHR EQALARLRSH
     PAQLKHKRDK HKDGSGERGE KDASKITTYP PGSVRFDCEL RAVQVSCGFH HSVVLMENGD
     VYTFGYGQHG QLGHGDVNSR GCPTLVQALP GPSTQVTAGS NHTAVLLMDG QVFTFGSFSK
     GQLGRPILDV PYWNAKPAPM PNIGSKYGRK ATWIGASGDQ TFLRIDEALI NSHVLATSEI
     FASKHIIGLV PASISEPPPF KCLLINKVDG SCKTFNDSEQ EDLQGFGVCL DPVYDVIWRF
     RPNTRELWCY NAVVADARLP SAADMQSRCS ILSPELALPT GSRALTTRSH AALHILGCLD
     TLAAMQDLKM GVASTEEETQ AVMKVYSKED YSVVNRFESH GGGWGYSAHS VEAIRFSADT
     DILLGGLGLF GGRGEYTAKI KLFELGPDGG DHETDGDLLA ETDVLAYDCA AREKYAMMFD
     EPVLLQAGWW YVAWARVSGP SSDCGSHGQA SITTDDGVVF QFKSSKKSNN GTDVNAGQIP
     QLLYRLPTSD GSASKGKQQT SEPVHILKRS FARTVSVECF ESLLSILHWS WTTLVLGVEE
     LRGLKGFQFT ATLLDLERLR FVGTCCLRLL RVYTCEIYPV SATGKAVVEE TSKLAECIGK
     TRTLLRKILS EGVDHCMVKL DNDPQGYLSQ PLSLLEAVLQ ECHNTFTACF HSFYPTPALQ
     WACLCDLLNC LDQDIQEANF KTSSSRLLAA VMSALCHTSV KLTSIFPIAY DGEVLLRSIV
     KQVSTENDST LVHRFPLLVA HMEKLSQSEE NISGMTSFRE VLEKMLVIVV LPVRNSLRRE
     NELFSSHLVS NTCGLLASIV SELTASALGS EVDGLNSLHS VKASANRFTK TSQGRSWNTG
     NGSPDAICFS VDKPGIVVVG FSVYGGGGIH EYELEVLVDD SEHAGDSTHS HRWTSLELVK
     GTYTTDDSPS DIAEIRLDKV VPLKENVKYA VRLRNYGSRT ANGDGGMTTV QCPDGVTFTF
     STCSLSSNGT NQTRGQIPQI LYYRSEFDGD LQSQLLSKAN EEDKNCSRAL SVVSTVVRAS
     KDLLHRALAV DADDIPELLS SSSLFSMLLP LIIAYIGPVA AAIPKVAVEV FGLVQQLLPS
     VAILNQKYAP PAFNPNQSTD STTGNQPEQG LSACTTSSHY AVIESEHPYK PACVMHYKVT
     FPECVRWMTI EFDPQCGTAQ SEDVLRLLIP VRTVQNSGYG PKLTSVHENL NSWIELKKFS
     GSSGWPTMVL VLPGNEALFS LETASDYVKD DKASFYGFKC FAIGYEFSPG PDEGVIQLEK
     ELANLGGVCA AALMKKDLAL PIGNELEEDL EILEEAALQV CKTHSGILGK GLALSHSPTI
     LEALEGNLPL QIQSNEQSFL DDFIACVPGS SGGRLARWLQ PDSYADPQKT SLILNKDDIR
     CGWPTTITVQ TKDQYGDVVH VPNMKVEVKA VPVSQKKMSL QQDQAKKPQR IPGSPAVTAA
     SSNTDMTYGG LASPKLDVSY EPMIVKEARY IAITMMKVYE NYSFEELRFA SPTPKRPSEN
     MLIRVNNDGT YCANWTPGAI GLYTLHVTID GIEIDAGLEV KVKDPPKGMI PPGTQLVKPK
     SEPQPNKVRK FVAKDSAGLR IRSHPSLQSE QIGIVKVNGT ITFIDEIHND DGVWLRLNDE
     TIKKYVPNMN GYTEAWCLSF NQHLGKSLLV PVDESKTNTD DFFKDINSCC PQEATMQEQD
     MPFLRGGPGM YKVVKTGPSG HNIRSCPNLR GIPIGMLVLG NKVKAVGEVT NSEGTWVQLD
     QNSMVEFCES DEGEAWSLAR DRGGNQYLRH EDEQALLDQN SQTPPPSPFS VQAFNKGASC
     SAQGFDYGLG NSKGDRGNIS TSSKPASTSG KSELSSKHSR SLKPDGRMSR TTADQKKPRG
     TESLSASESL ILKSDAAKLR SDSHSRSLSP NHNTLQTLKS DGRMPSSSRA ESPGPGSRLS
     SPKPKTLPAN RSSPSGASSP RSSSPHDKNL PQKSTAPVKT KLDPPRERSK SDSYTLDPDT
     LRKKKMPLTE PLRGRSTSPK PKSVPKDSTD SPGSENRAPS PHVVQENLHS EVVEVCTSST
     LKTNSLTDST CDDSSEFKSV DEGSNKVHFS IGKAPLKDEQ EMRASPKISR KCANRHTRPK
     KEKSSFLFKG DGSKPLEPAK QAMSPSVAEC ARAVFASFLW HEGIVHDAMA CSSFLKFHPE
     LSKEHAPIRS SLNSQQPTEE KETKLKNRHS LEISSALNMF NIAPHGPDIS KMGSINKNKV
     LSMLKEPPLH EKCEDGKTET TFEMSMHNTM KSKSPLPLTL QHLVAFWEDI SLATIKAASQ
     NMIFPSPGSC AVLKKKECEK ENKKSKKEKK KKEKAEVRPR GNLFGEMAQL AVGGPEKDTI
     CELCGESHPY PVTYHMRQAH PGCGRYAGGQ GYNSIGHFCG GWAGNCGDGG IGGSTWYLVC
     DRCREKYLRE KQAAAREKVK QSRRKPMQVK TPRALPTMEA HQVIKANALF LLSLSSAAEP
     SILCYHPAKP FQSQLPSVKE GISEDLPVKM PCLYLQTLAR HHHENFVGYQ DDNLFQDEMR
     YLRSTSVPAP YISVTPDASP NVFEEPESNM KSMPPSLETS PITDTDLAKR TVFQRSYSVV
     ASEYDKQHSI LPARVKAIPR RRVNSGDTEV GSSLLRHPSP ELSRLISAHS SLSKGERNFQ
     WPVLAFVIQH HDLEGLEIAM KQALRKSACR VFAMEAFNWL LCNVIQTTSL HDILWHFVAS
     LTPAPVEPEE EEDEENKTSK ENSEQEKDTR VCEHPLSDIV IAGEAAHPLP HTFHRLLQTI
     SDLMMSLPSG SSLQQMALRC WSLKFKQSDH QFLHQSNVFH HINNILSKSD DGDSEESFSI
     SIQSGFEAMS QELCIVMCLK DLTSIVDIKT SSRPAMIGSL TDGSTETFWE SGDEDKNKTK
     NITINCVKGI NARYVSVHVD NSRDLGNKVT SMTFLTGKAV EDLCRIKQVD LDSRHIGWVT
     SELPGGDNHI IKIELKGPEN TLRVRQVKVL GWKDGESTKI AGQISASVAQ QRNCEAETLR
     VFRLITSQVF GKLISGDAEP TPEQEEKALL SSPEGEEKVY NATSDADLKE HMVGIIFSRS
     KLTNLQKQVC AHIVQAIRME ATRVREEWEH AISSKENANS QPNDEDASSD AYCFELLSMV
     LALSGSNVGR QYLAQQLTLL QDLFSLLHTA SPRVQRQVTS LLRRVLPEVT PSRLASIIGV
     KSLPPADISD IIHSTEKGDW NKLGILDMFL GCIAKALTVQ LKAKGTTITG TAGTTVGKGV
     TTVTLPMIFN SSYLRRGESH WWMKGSTPTQ ISEIIIKLIK DMAAGHLSEA WSRVTKNAIA
     ETIIALTKME EEFRSPVRCI ATTRLWLALA SLCVLDQDHV DRLSSGRWMG KDGQQKQMPM
     CDNHDDGETA AIILCNVCGN LCTDCDRFLH LHRRTKTHQR QVFKEEEEAI KVDLHEGCGR
     TKLFWLMALA DSKTMKAMVE FREHTGKPTT SSSEACRFCG SRSGTELSAV GSVCSDADCQ
     EYAKIACSKT HPCGHPCGGV KNEEHCLPCL HGCDKSATSL KQDADDMCMI CFTEALSAAP
     AIQLDCSHIF HLQCCRRVLE NRWLGPRITF GFISCPICKN KINHIVLKDL LDPIKELYED
     VRRKALMRLE YEGLHKSEAI TTPGVRFYND PAGYAMNRYA YYVCYKCRKA YFGGEARCDA
     EAGRGDDYDP RELICGACSD VSRAQMCPKH GTDFLEYKCR YCCSVAVFFC FGTTHFCNAC
     HDDFQRMTSI PKEELPHCPA GPKGKQLEGT ECPLHVVHPP TGEEFALGCG VCRNAHTF
//
